A randomized phase II clinical trial of a fasting-mimic diet prior to chemotherapy to evaluate the impact on toxicity and efficacy.
Mahshid Shelechi, Denice Tsao-Wei, Jacek K. Pinski, Irene Kang et autres
0 citationsJournal of Clinical Oncology
Janice Lu
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
179Publications signalées
3871Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Advanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyBreast Cancer Treatment StudiesCancer Genomics and Diagnostics
Publications récentes
Baseline circulating tumor cells and association with early resistance in patients with metastatic breast cancer undergoing palbociclib therapy.
Qiang Zhang, Justin Weicheng Zhang, Andrew A. Davis, Paolo D'Amico et autres
0 citationsJournal of Clinical Oncology
Multicenter Interspecialty Consensus on Experimental Oncology Drug–Related Ocular Adverse Event Reporting
Neel D. Pasricha, Stella K. Kim, Asim V. Farooq, Ethan S. Lindgren et autres
6 citationsJAMA Ophthalmology
Abstract P2-10-20: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)
Joyce O’Shaughnessy, Kashif Ali, Sami M. Ali, Kevin Kalinsky et autres
0 citationsClinical Cancer Research
Abstract P1-03-22: Comprehensive characterization of the androgen receptor in male breast cancer
Priya Jayachandran, Sachin Kumar Deshmukh, Sharon Wu, Jennifer R. Ribeiro et autres
0 citationsClinical Cancer Research
Abstract P1-01-25: Elacestrant vs SOC in ER+, HER2- advanced or metastatic breast cancer (mBC) with ESR1-mutated tumors: ESR1 allelic frequencies and clinical activity from the phase 3 EMERALD trial
Aditya Bardia, Javier Cortés, Francois Clement-Bidard, Guillermo Streich et autres
2 citationsClinical Cancer Research
Abstract P2-07-16: Rising ESR1 Mutations in Circulating Tumor DNA (ctDNA) Mediate Endocrine Therapy (ET) Resistance to Everolimus and ET but Retain Sensitivity to Fulvestrant in HR+/HER2- Metastatic Breast Cancer (MBC)
Janice Lu, Natalie Knox Heater, Lisa Flaum, Huiping Liu et autres
0 citationsClinical Cancer Research
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
Denise M. Wolf, Christina Yau, Michael J. Campbell, Annuska M. Glas et autres
5 citationsJCO Precision Oncology
Integrating dynamic analysis of serial ctDNA testing to enhance diagnostic and prognostic assessments in patients with metastatic breast cancer.
Qiang Zhang, Andrew A. Davis, Paolo D’Amico, Jianhua Jiao et autres
0 citationsJournal of Clinical Oncology
Characterization of the ctDNA mutational landscape in HER2-positive metastatic breast cancer patients who developed cancer therapy-related cardiac dysfunction.
Diana Jaber, Natalie Knox Heater, Surbhi Warrior, Nepheli Raptis et autres
0 citationsJournal of Clinical Oncology
The use of circulating tumor DNA (ctDNA) to evaluate need for additional targeted therapies in HER2 positive metastatic breast cancer (MBC).
Surbhi Warrior, Diana Jaber, Natalie Knox Heater, Yangruijue Ma et autres
1 citationJournal of Clinical Oncology
Genomic landscapes of HR+HER2- metastatic breast cancer: Insights from ctDNA profiling in the U.S. and China.
Huiping Li, Qiang Zhang, Fangyuan Zhao, Xiaoran Liu et autres
0 citationsJournal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.